AcelRx Pharmaceuticals, Inc. today announced that an abstract, entitled, “Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets” has been accepted for podium presentation at Plastic Surgery: The Meeting 2022, taking place October 27-30, 2022 in Boston, MA.
HAYWARD, Calif., Aug. 11, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, “Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets” has been accepted for podium presentation at Plastic Surgery: The Meeting 2022, taking place October 27-30, 2022 in Boston, MA. The abstracts will be presented at the meeting and run from Thursday, October 27, 2022 at 1:30 pm until Sunday, October 30, 2022 at 4:30 pm ET. The time of the podium presentation is currently pending, but will be posted on the Investors/Events section of the AcelRx website once that information becomes available. The presentation will be conducted as in-person event only with no virtual or replay option made available. About Plastic Surgery: The Meeting 2022 Plastic Surgery: The Meeting brings together plastic surgeons from countries around the globe. This annual event is the premier educational and networking event of the year for both domestic and international plastic surgeons, and is considered to serve as the annual meeting of The American Society of Plastic Surgeons (ASPS). ASPS is the largest plastic surgery specialty organization in the world representing 94% of all board-certified plastic surgeons in the U.S. including more than 11,000 plastic surgeons worldwide. ASPS is considered a global institution and leading authority on cosmetic and reconstructive plastic surgery. The meeting also convenes members of The Plastic Surgery Foundation (PSF), the American Society of Maxillofacial Surgeons (ASMS), and the World Society for Simulation Surgery. About DSUVIA (sufentanil sublingual tablet), 30 mcg This release is intended for investors only. For more information, including important safety information and black box warning for DSUVIA, please visit www.DSUVIA.com. About AcelRx Pharmaceuticals, Inc. This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc. | ||
Company Codes: NASDAQ-NMS:ACRX |